Clinical Trials Logo

Filter by:
NCT ID: NCT03724773 Withdrawn - Clinical trials for Closed Fracture of Shaft of Ulna

Long-Arm vs Sugar-Tong

LAST
Start date: March 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a sugar-tong splint is as effective as a long-arm cast in maintaining reduction of pediatric forearm shaft fractures in a randomized, prospective manner. Consented participants will be randomly assigned to be treated with either a sugar-tong splint or a long-arm cast (both standard of care treatments) in REDCap. Each participant will have a 50/50 chance of being assign to either treatment.

NCT ID: NCT03723577 Withdrawn - Wound Clinical Trials

An Evaluation of a Fibrillar Collagen Dressing to Treat Chronic, Stalled Lower-extremity Wounds

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

Patients who meet the inclusion criteria will be provided with fibrillar collagen powder dressing. The powder dressing will be used in accordance with its label. After cleansing the wound by the clinical site staff, the powder is placed directly on the wound, and then the wound will be covered with an appropriate moisture retentive secondary dressing. Patients will visit the clinic twice a week to have the powder re-applied. Wound evaluations will take place once a week at the outpatient clinic, with the intervention lasting up to twelve weeks. Concurrent standard of care, such as compression for venous ulcers, will be provided.

NCT ID: NCT03722381 Withdrawn - Pharmacokinetics Clinical Trials

Evaluation of Amlodipine Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis

Start date: January 2020
Phase:
Study type: Observational

The current study will evaluate the plasma pharmacokinetics of amlodipine in a cohort of 8 adult volunteers who are receiving regular hemodialysis treatment (HD) 3 days a week for 4 hours each day and have been taking a total daily dose of 5-10 mg of amlodipine besylate for >30 days as part of their usual care. Blood sampling will occur over 13 hours, with frequent sampling during HD and in the 4 hours after termination of HD treatment. The 8 subjects will all receive their prescribed total daily dose of 5-10 mg 5 hours prior to HD treatment. The pre-HD sample will also be sent for pharmacogenomics genotyping. Safety and pharmacodynamic assessments (blood pressure (BP) and heart rate (HR) assessments) will be performed throughout the study. Axiom Precision Medicine Research Array (Affymetrix, Santa Clara, CA) will be used to evaluate genotype of CYP3A4. CYP3A4 phenotype will be evaluated using the ratio of parent drug to metabolite. Non-compartmental analyses will be performed to compare maximum concentrations (Cmax), time to maximum concentration and area under the curve from time 0 to the last measurable sample (AUClast) between the two phases. Compartmental analyses will be performed to construct a model to explain time-dependent changes in amlodipine clearance. Monte Carlo simulations will be performed to compare amlodipine pharmacokinetic profiles on and off HD.

NCT ID: NCT03721211 Withdrawn - Breast Cancer Clinical Trials

Imaging With [11C]Martinostat in Breast Cancer

Start date: February 1, 2020
Phase: Phase 1
Study type: Interventional

This research study is studying a PET imaging tracer as a possible means of imaging breast cancer. The imaging agent involved in this study is: -[11C]Martinostat (called C-eleven-Martinostat)

NCT ID: NCT03720483 Withdrawn - Clinical trials for Idiopathic Pulmonary Fibrosis (IPF)

Inhaled NAC in Treatment of IPF

Start date: January 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.

NCT ID: NCT03719898 Withdrawn - Clinical trials for Anaplastic Large Cell Lymphoma, ALK-Positive

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Start date: December 6, 2018
Phase: Phase 2
Study type: Interventional

FDA approved drugs to treat patients with relapsed or refractory anaplastic large cell lymphoma (ALCL) has a median progression free survival of 20 months. Majority of patients relapse in 2 years. This study will evaluate overall response rate of next generation ALK inhibitor brigatinib in ALK positive ALCL patients by overcoming mechanisms of resistance to ALK inhibitors on cancer patients.

NCT ID: NCT03719560 Withdrawn - Clinical trials for Diffuse Large B Cell Lymphoma

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

BrUOG-377
Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

Phase 2 single-institution trial of early systemic central nervous system prophylaxis in high-risk diffuse large B-cell lymphoma

NCT ID: NCT03718650 Withdrawn - Pancreatic Cancer Clinical Trials

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

Start date: April 1, 2021
Phase: Early Phase 1
Study type: Interventional

At present there is no validated prognostic tool for patients with resectable pancreatic cancer (RPC) to determine how best to tailor individual therapy. This study is to see if tumor features in blood and imaging prior to surgery correspond with tumor heterogeneity in the specimen after surgery.

NCT ID: NCT03716219 Withdrawn - Asthma in Children Clinical Trials

The Effect of 10-Week Exercise Training on Children With Asthma

Start date: October 10, 2013
Phase: N/A
Study type: Interventional

The goal of this research is to determine whether 10-weeks of exercise training can benefit asthmatic children and young adults with a history of exercise-induced bronchoconstriction (EIB). The investigators will also study an exciting newly discovered aspect of gene expression regulation in the white blood cells known as epigenetics: a process that takes place when genomic changes happen as a result of exposure to the environment. This study is based on emerging exciting new data from this and other laboratories demonstrating that (a) white blood cells play an important role in bronchoconstriction in children, (b) gene and cytokine expression in circulating white blood cells are abnormal in asthma and (c) brief exercise may change genomic and inflammatory- profiles of these cells.Physical activity is an essential component of growth and health in children, thus, this research will lead to improved clinical uses of exercise as preventive and adjunctive therapy in the current epidemic of childhood asthma

NCT ID: NCT03714867 Withdrawn - Clinical trials for Head and Neck Cancer

Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery

Start date: March 22, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate and reduce pain and improve quality of life in patients being treated for head and neck cancer with primary tumor resection and bilateral neck dissections. Patients will be randomly assigned to receive either pre-operative pregabalin (Lyrica) or a placebo. Patients and investigators will be blinded to which medication patients receive, and all patients will receive the same postoperative pain medication regimen with appropriate pain treatment as needed. Patients will be asked to fill out surveys prior to surgery, while in the hospital after surgery, and at each follow-up appointment for up to 24 months.